Novel Oral Anticoagulants in Peripheral Artery Disease: Current Evidence

Author(s): A. Koutsoumpelis*, C. Argyriou, K.M. Tasopoulou, E.I. Georgakarakos, G.S. Georgiadis

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 38 , 2018

Become EABM
Become Reviewer
Call for Editor


Background: Peripheral artery disease is a common manifestation of systemic atherosclerosis which strongly correlates to cardiovascular morbidity and mortality. In addition, the progression of peripheral artery disease leads to an increased risk of limb loss. In order to reduce these events, the benchmark of treatment and research over the last years has been the antiplatelet therapy which aims at inhibition of platelet aggregation. Over the last years, new studies combining antiplatelet agents in different therapeutic schemes have been proven efficacious. Unfortunately, patients remain still at high risk of CV events. Novel Oral Anticoagulants have been introduced as alternatives to warfarin, in the prevention and treatment of venous thromboembolism. The rationale of using medication which acts on platelet activation and the coagulation pathway of thrombosis has led investigators to examine the role of Noac's in preventing CV events in patients with peripheral artery disease, stable or unstable.

Methods: The aim of this study is to review the current evidence with respect to recently published studies concerning the use of Novel anticoagulants in peripheral artery disease.

Results: The Compass trial has shown that a combination of rivaroxaban with traditional therapy may produce promising results in reducing amputation rates, stroke, cardiac events, and mortality, however, there are still safety issues with bleeding requiring acute care. The ePAD study has provided us with insight concerning safety and efficacy after peripheral angioplasty or stenting and actually the need for further research. The Voyager Pad study, following the steps of Compass, is studying the effect and safety of the addition of rivaroxaban to traditional therapy in the highest risk population aka patients undergoing peripheral revascularization. The evidence concerning patients with concomitant atrial fibrillation appears to be insufficient, however, recent guidelines propose the use of novel oral anticoagulants.

Conclusion: For the time being, novel oral anticoagulants in combination with aspirin may provide an alternative treatment in PAD, however, it is deemed necessary to identify patient subgroups who will benefit the most.

Keywords: PAD, CAD, antithrombotic therapy, oral anticoagulants, atrial fibrillation, thrombosis, antiplatelet.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [4511 - 4515]
Pages: 5
DOI: 10.2174/1381612825666181226151959
Price: $65

Article Metrics

PDF: 85
HTML: 37
PRC: 2